PubRank

Phyllis I Spuls

Author PubWeight™ 22.44‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003 2.12
2 Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010 1.77
3 The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol 2009 1.07
4 Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 2011 1.04
5 Interventions for nail psoriasis. Cochrane Database Syst Rev 2013 0.97
6 Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol 2011 0.94
7 Health-related quality of life in patients with cutaneous rosacea: a systematic review. Acta Derm Venereol 2015 0.92
8 Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology 2002 0.90
9 The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc 2004 0.89
10 Etanercept: an overview of dermatologic adverse events. Arch Dermatol 2011 0.87
11 Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol 2008 0.87
12 Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol 2004 0.86
13 Validation and refinement of the Millennium Criteria for atopic dermatitis. J Dermatol 2011 0.86
14 Topical treatments in psoriasis: today and tomorrow. Clin Dermatol 2008 0.82
15 Accuracy and reliability of teledermatoscopy with images taken by general practitioners during everyday practice. J Telemed Telecare 2013 0.81
16 Tertiary teledermatology: a systematic review. Telemed J E Health 2010 0.80
17 Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation. Acta Derm Venereol 2016 0.78
18 Measurement properties of outcome measures for vitiligo. A systematic review. Arch Dermatol 2012 0.78
19 The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab's withdrawal. Arch Dermatol 2009 0.78
20 Analysis of risk factors in psoriatic patients with methotrexate-induced increases in transaminase levels. Arch Dermatol 2004 0.77
21 Prospective comparison of three guideline development methods for treatment of actinic keratosis. BMJ Qual Saf 2011 0.77
22 Atopic eczema or atopiform dermatitis. Exp Dermatol 2010 0.76
23 Intralesional Bleomycin Injections for Vascular Malformations: A Systematic Review and Meta-Analysis. Plast Reconstr Surg 2016 0.76
24 The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: study protocol for a multicenter randomized controlled trial. Trials 2012 0.75
25 Treatment of Basal Cell Carcinoma Using a One-Stop-Shop With Reflectance Confocal Microscopy: Study Design and Protocol of a Randomized Controlled Multicenter Trial. JMIR Res Protoc 2015 0.75
26 Evaluation of a tertiary teledermatology service between peripheral and academic dermatologists in the Netherlands. Telemed J E Health 2014 0.75
27 A pilot study on tertiary teledermatology: feasibility and acceptance of telecommunication among dermatologists. J Telemed Telecare 2010 0.75
28 Towards More Shared Decision Making in Dermatology: Develop-ment of Evidence-based Decision Cards for Psoriasis and Atopic Eczema Treatments. Acta Derm Venereol 2020 0.75
29 Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries. Acta Derm Venereol 2016 0.75